Abstract
See related article, page 265. Atrial fibrillation (AF) is widely recognized as the most common cause of cardioembolic stroke in those aged >55 years. Less well appreciated are silent embolic infarcts and their impact on cognitive decline and vascular dementia. Hence, the prevention of both clinical and silent brain infarcts is the primary goal of effective AF treatment. Indeed, entire industries have been spawned to prevent stroke in AF. Warfarin is established as the benchmark stroke prevention treatment, although its risks and limitations are well known, not the least of which is underuse by …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
